InKemia and ADVentura Capital join forces to create new biotechnology spin-offs
These two companies will work together over the coming five years and plan to follow the Plasmia Biotech business model.
By Biocat
IUCT Emprèn, the division of InKemia IUCT Group devoted to managing companies in which it holds a stake, and Catalan accelerator ADVentura Capital have signed an agreement in order to launch at least one spin-off per year over the coming five years from InKemia’s technology portfolio. The two companies have joined forces to start designing their first joint action.
ADVentura Capital will locate and prioritize business opportunities and, once identified, develop a business plan and search for financial and industrial partners in order to begin business activity. The company is presided over by international investor Oliver Rothschild and CEO Nigel Fleming, a serial entrepreneur with 25 years of experience in business development in the biotechnology arena.
IUCT Emprèn contributes the technology necessary for proper development and operations of the spin-offs that come out of this joint venture. InKemia plans to follow the business model used with Plasmia Biotech, its first spin-off created through the transfer of its own patents that develops antiviral and antitumor raw materials from enzymatic synthesis of nucleoside analogs. Last December, businessman José Manuel Lara acquired 30% of the company.
Both parties have made declarations expressing their satisfaction with the agreement and their hopes to see the first results shortly.
This year, InKemia IUCT Group has confirmed a €2.5 millions capital increase and invested €240,000 in the company Biodan Sciences through its capital fund. Less than a year since it went public on the Alternative Stock Market (MAB) the company has already consolidated its position as one of the most powerful in the biotechnology arena in Catalonia.